Completed PHASE1 INTERVENTIONAL 6-arm NCT01701752

Influenza A Vaccine (FP-01.1) Formulated With and Without Adjuvant, in the Presence or Absence of a Single Administration of a Trivalent Inactivated Influenza Virus Vaccine in Older Adults

A Randomised, Double Blind, Double Observer Study to Assess Repeated Administration of a Single Dose of an Influenza A Vaccine (FP-01.1) Formulated With and Without Adjuvant, in the Presence or Absence of a Single Dose of a Trivalent Inactivated Influenza Virus Vaccine in Subjects 65 to 74 Years of Age.

Sponsor: Immune Targeting Systems Ltd

Conditions Influenza A

Interventions Adjuvant + TIV FP-01.1 FP-01.1 + Placebo FP-01.1 + TIV FP-01.1-Adjuvant FP-01.1-Adjuvant + Placebo FP-01.1-Adjuvant + TIV Placebo Placebo + TIV

Updated 5 times since 2017 Last updated: Jul 26, 2013 Started: Sep 30, 2012 Primary completion: Apr 30, 2013 Completion: Apr 30, 2013

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT01701752, this PHASE1 trial focuses on Influenza A and remains completed. Sponsored by Immune Targeting Systems Ltd, it has been updated 5 times since 2012, reflecting limited change activity. This study is part of the global effort to build evidence for infectious disease interventions.

Status Flow

Change History

5 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE1
Jul 2024 — Sep 2024 [monthly]

Completed PHASE1
Jan 2021 — Jul 2024 [monthly]

Completed PHASE1
Jun 2018 — Jan 2021 [monthly]

Completed PHASE1
Jan 2017 — Jun 2018 [monthly]

Completed PHASE1

First recorded

Sep 2012

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Immune Targeting Systems Ltd

Data source: Immune Targeting Systems Ltd

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

No location information available.